Drug Profile
Tralesinidase alfa - BioMarin Pharmaceutical
Alternative Names: Alpha-N-acetyglucosaminidase-insulin-like-growth-factor-2 fusion protein; AX-250; BMN 250; NAGLU-IGF2 fusion proteinLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator BioMarin Pharmaceutical
- Class Acetylglucosaminidases; Recombinant fusion proteins
- Mechanism of Action Alpha N acetyl D glucosaminidase replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Mucopolysaccharidosis III
Most Recent Events
- 09 Aug 2022 Allievex Corporation plans a phase IIIb/IV trial for Mucopolysaccharidosis III (In children, In adults, In the elderly) in the USA, Colombia, Germany, Turkey and the United Kingdom (Intracerebroventricular, Infusion) in September 2022 (NCT05492799)
- 23 Jul 2020 Allievex Corporation completes the phase I/II trial in Mucopolysaccharidosis III (In Infants, In children) in Germany, Spain, Taiwan, UK, Turkey, Colombia and USA (Intracerebral) (NCT02754076)
- 23 Oct 2019 Tralesinidase alfa to be licensed to Allievex worldwide